In the treatment of cUTI
caused by susceptible Enterobacteriaceae1
- Escherichia coli
- Klebsiella pneumoniae
- Enterobacter cloacae species complex
New Technology Add-On
Payment (NTAP) Status
VABOMERE™ (meropenem and vaborbactam) in vitro activity against susceptible Enterobacteriaceae* in the presence of some beta-lactamases and extended-spectrum
Recommended dosing in patients with complicated urinary tract infections (cUTI)
≥18 years of age.
Order VABOMERE using standard ordering procedure through your wholesaler.
Download the Order Sheet for more information.
VABOMERE is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
Reference: 1.Vabomere [package insert]. Lincolnshire, IL: Melinta Therapeutics, Inc.; 2018.